You are here

Obesity Treatment Contrave Succeeds in “Real World” Study

Extended-release naltrexone/bupropion superior to usual care

The phase 3, randomized, open-label IGNITE trial was designed to evaluate the use of Contrave (naltrexone and bupropion extended-release tablets, Orexigen Therapeutics) in combination with a commercially available lifestyle-intervention program compared with usual care in a “real world” weight-loss setting. The results showed that treatment with Contrave, when used in a manner consistent with prescribing information in the United States, resulted in a significant reduction in body weight compared with usual care.

The IGNITE study evaluated 242 obese (body mass index [BMI]: 30 to 45 kg/m2) or overweight (BMI: 27 to 45 kg/m2) adults 18 to 60 years of age with dyslipidemia and/or controlled hypertension. During an initial 26-week controlled-treatment phase, the patients were randomly assigned to receive either Contrave in combination with a commercially available comprehensive lifestyle-intervention program (i.e., a telephone- and internet-based program that included a nutrition and exercise program with individualized goal-setting) or usual care (i.e., standard diet and exercise advice from the study site).

At week 16, participants receiving Contrave had to achieve at least 5% weight loss to continue therapy, consistent with U.S. prescribing information. The study’s primary endpoint was the percent change in body weight per protocol population; secondary endpoints included the percentage of patients achieving weight loss of at least 5%, 10%, or 15% of baseline body weight.

After 26 weeks of treatment, participants in the Contrave group lost significantly more weight compared with the usual-care group (9.5% versus 0.9%, respectively; P < 0.0001). In addition, significantly more Contrave-treated patients achieved three weight loss thresholds compared with those given usual care:

  • 85% versus 12% had 5% or greater weight loss (P < 0.0001)
  • 42% versus 4% had 10% or greater weight loss (P < 0.0001)
  • 13% versus 0% had 15% or greater weight loss (P value not determined)

Significantly greater reductions in obesity-related risk factors were observed in Contrave-treated participants compared with those receiving usual care, including triglycerides, waist circumference, glucose, insulin, and a measure of insulin resistance. Contrave-treated participants also experienced a significantly greater increase in high-density lipoprotein (“good”) cholesterol.

Contrave, approved by the FDA in September 2014, is indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type-2 diabetes mellitus, or dyslipidemia).

Source: Orexigen Therapeutics; January 6, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress